



ADVİK LABORATORIES LIMITED

ALL/BSE/ASE/OUT-BM/Q3/2021

Dated: 12th February, 2021

The Manager (Listing)
BSE Limited,
1st Floor, P.J. Towers
Dalal Street, Mumbai – 400001

Sub: Outcome of the Board Meeting and Submission of Unaudited Financial Results for the quarter ended 31st December, 2020 as required u/r 33 of the SEBI (LODR) Regulations, 2015.

Ref : BSE Scrip Code 531686; ASE Scrip Code- 01638 (ADVİK LABO)

Dear Sir,

This is to inform you that in pursuance to Regulation 33 of SEBI (LODR) Regulations, 2015, the Board of Directors of the Company in its meeting held on Friday, 12th February, 2021 at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi – 110001 and concluded just now has, inter-alia, transacted the following business:


1. Considered and Approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2020.
2. Considered and taken on record Limited Review Report submitted by the Statutory Auditors of the Company for the Unaudited Financial Results of the Company for the quarter December 31, 2020.
3. The Board also considered and took note of the OTS Sanction letter received from Indian Overseas Bank wherein the said Bank has approved the One Time Settlement offer for Rs. 645.00 Lakhs made by the Company to settle the outstanding loan obtained by the Company from the said Bank. The Board also took note of the fact that the Company has to clear the entire outstanding dues of Indian Overseas Bank on or before 18th April, 2021 as per the terms and conditions of the aforesaid OTS.
4. The Board, pursuant to observations made by the Statutory Auditors of the Company and keeping in view the efforts made by the Company to recover the doubtful debts, has decided to write off the receivables & loans & advances aggregating to Rs. 346.92 lacs, which are very old & not recoverable and hence considered to be bad debts.

Further, pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, a copy of the aforesaid unaudited Financial Results for the quarter ended 31st December, 2020 alongwith Limited Review Report of the Statutory Auditors thereon is enclosed herewith for your kind perusal.

Kindly treat this information as information submitted under Regulation 30 of SEBI (LODR) Regulations, 2015. We request you to take the aforesaid information in your records.

Thanking you.

For Advik Laboratories Limited


Peeyush Kumar Aggarwal
Managing Director
DIN: 00090423



Encl: As Above

CC:

The Manager (Listing)
Ahmedabad Stock Exchange Limited
1st Floor, Kamdhenu Complex
Opp. Sahajanand College,
Panjara Pole, Ambawadi, Ahmedabad – 380015

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi - 110001

Phones : 011-42424884, 43571040-45, Fax : 011-43571047

Regd. Office & Factory : 138, ROZ-Ka Meo, Industrial Area, Sohna - 122103 (Distt. Mewat), Haryana

Phones : 0124-2362471 E-mail : mail@advikindia.com Website : www.advikindia.com

**ADVIL LABORATORIES LIMITED**

Regd. Off. :138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat Haryana - 122103

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED
DECEMBER 31, 2020**

CIN : L74899HR1994PLC038300

Sr No	Particulars	(Rs in Lacs except EPS)					
		For the Quarter ended			For the nine months ended		Year Ended
		31-Dec-20 (Unaudited)	30-Sep-20 (Unaudited)	31-Dec-19 (Unaudited)	31-Dec-20 (Unaudited)	31-Dec-19 (Unaudited)	31-Mar-20 (Audited)
1	Income from Operation						
	(a) Net Sales/Revenue from Operations	-	-	-	-	-	-
	(b) Other Operating Income	-	-	-	-	0.44	0.44
	(c) Other Income	0.48	0.85	0.74	1.33	0.96	1.06
	Total Income	0.48	0.85	0.74	1.33	1.40	1.50
2	Expenses						
	a) Cost of Materials consumed	-	-	-	-	-	0.08
	b) Purchase of Stock-in-trade	-	-	-	-	-	-
	c) Changes in Inventory of Finished goods, Work-in-progress and Stock-in-trade	-	-	-	-	-	-
	d) Employee Benefits Expenses	9.81	9.53	10.62	28.99	32.51	45.05
	e) Finance Costs	0.02	0.01	0.03	0.04	0.10	0.02
	f) Bad Debts	346.92	-	-	346.92	-	-
	f) Depreciation and Amortisation expense	14.17	14.16	14.64	42.49	43.93	57.26
	g) Other expenses	4.98	5.94	3.47	15.32	12.62	22.74
	Total Expenses	375.90	29.64	28.76	433.76	89.16	125.15
3	Profit/(Loss) before Exceptional items and tax (1-2)	(375.42)	(28.79)	(28.02)	(432.43)	(87.76)	(123.65)
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before tax (3 + 4)	(375.42)	(28.79)	(28.02)	(432.43)	(87.76)	(123.65)
6	Tax Expense						
	- Current tax	-	-	-	-	-	-
	- Deferred tax	(2.03)	(2.03)	(2.27)	(6.09)	(6.80)	(6.96)
	Total Tax Expenses	(2.03)	(2.03)	(2.27)	(6.09)	(6.80)	(6.96)
7	Profit/(Loss) for the period (5-6)	(373.39)	(26.76)	(25.75)	(426.34)	(80.96)	(116.69)
8	Other Comprehensive Income (net of tax)	0.08	0.08	0.33	0.24	0.99	0.28
9	Total Comprehensive Income for the period (7+8)	(373.31)	(26.68)	(25.42)	(426.10)	(79.97)	(116.41)
10	Paid-up equity share capital (face value of Rs 10/- per	1,911.14	1,911.14	1,911.14	1,911.14	1,911.14	1,911.14
11	Earning per share (EPS) of Rs 10/- each (not annualized)						
	(1) Basic	(1.95)	(0.14)	(0.13)	(2.23)	(0.42)	(0.61)
	(2) Diluted	(1.95)	(0.14)	(0.13)	(2.23)	(0.42)	(0.61)


NOTES:-

1	The above Financial Results for the quarter & nine months ended December 31, 2020 has been reviewed by the Audit Committee and thereafter approved by the Board of Directors & taken on record at its meeting held on February 12, 2021. A Limited review of the same has been carried out by the Statutory Auditors.
2	The Company operates in a single segment viz pharmaceuticals formulations and the results pertain to a single segment in accordance with IND AS 108-Operating Segment.
3	The format for un-audited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016. IND AS and Schedule III (Division II) to the Companies Act, 2013 applicable to the companies that are required to comply with IND AS.
4	In the absence of any orders during the quarter under review, there is a decline in the operating activities of the company. The company is trying to find the prospective buyers & believes that the new deals would be finalized soon.
5	During the quarter under review, the management of the company, as per the observations made by the statutory auditor & efforts made by the company, has decided to write off the receivables & loans & advances aggregating to Rs. 346.92 lacs which are very old & not recoverable, hence considered to be bad.



	Auditor's Observation:-
6	<p>a) Due to default in payments of bank loans, the company's accounts have been classified as Non-Performing Assets (NPA) by the bank. Indian Overseas Bank has not charged interest on Cash credit & Term Loan Limits. During the period under review no provision has been made for such interest in the books of account of the company and to that extent bank's loan liability and total loss is understated by Rs. 872.62 lacs plus penal charges that the bank may charge. The amount disclosed in the Financial Statements is subject to confirmation adjustments, if any.</p> <p>b) The company had recorded the cost of the investment at the face value of the equity shares issued and had not determined the fair value as required by IND AS. In the absence of the fair value of the securities acquired we are unable to express an opinion on the value of the investment recorded.</p> <p>c) The stock of raw material and work in progress has been valued at cost price. In the current quarter there has been no production, it may have impact on profitability to the extent of its cost less realizable amount if any.</p>
7	<p>Our explanation to Auditor's Observation:-</p> <p>a. The Company's accounts had become Non-Performing Assets (NPA) with Indian Overseas Bank (IOB) and due to this reason, IOB has stopped charging interest from the company on its outstanding debts. In view of the above, the company has not charged to statement of Profit & Loss account Interest expenses of Rs. 50.33 Lacs and related penal interest & other charges, if any, for the reported period, in respect of delay of repayments of borrowings from the bank. Further liability for interest expenses of Rs. 822.29 lacs till 30/09/2020 has not been accounted for. The company has made necessary efforts to reach One Time Settlement with IOB & had accordingly again sent the One Time Settlement proposal with IOB which has been approved by the Bank. As per terms of the OTS, company is supposed to clear the OTS amount on or before 19/04/2021. Accordingly, our company has made the partial payments towards the settlement of the aforesaid loan as per the terms and conditions mentioned in said OTS.</p> <p>b. The company has misplaced/lost the share certificates of the Investment made by it in unquoted equity shares of other companies during the shifting of its records. Hence these share certificates are not physically held by the company. The Company has sent various request letters to the companies in which it has made investments for issue of duplicate share certificates. However, till date the company has not received any reply from these companies. In order to ensure the compliance of IND AS in true letter and spirits, the company is also trying to ascertain the fair market value of its investments.</p> <p>c. In the absence of any orders in the recent past, there is a decline in the operating activities of the company. Hence, the stock of raw material which remained unused is left with the company and is accordingly, reflected in its books of Accounts. The management of the Company is making necessary efforts to find the perspective buyers and to procure the new orders. The Company's management strongly believes that the new deals would be finalized soon. The unused stock of raw material would be utilized in manufacturing finished goods, once the new orders would be procured by the Company. Therefore, the company has valued its stock of raw material at cost price and not at its realizable amount because the Company intends to carry on its operations in near future and to use the stock of raw materials available with it in manufacturing activities as soon as the company will procure new orders.</p>
8	Company has made the payment of outstanding Annual Listing Fees to BSE, where the shares of the Company is listed & hence sent the request letter to BSE for revocation the suspension of equity shares of the company alongwith defreeze the holding of promoters of our company and also recall any other punitive action taken against our company, if any.
9	The Company is assessing the possible effects that may results from the pandemic COVID-19 on the carrying amount of assets/liabilities. The impact assessment of COVID-19 is a continuing process given its nature and duration. The Company will continue to monitor this aspect for any material changes in future economic conditions.
10	Previous year/period figures have been regrouped/arranged, wherever necessary to make them comparable with the current period figure.

For and on behalf of Board of Directors of Advik Laboratories Ltd.


 Peeyush Kumar Aggarwal
 Chairman
 DIN : 00090423



Place: New Delhi
Date : 12th February, 2021



**Independent Auditors Review Report on Quarterly Unaudited Standalone Financial Results
of the company for the quarter and nine months ended December, 2020
(Pursuant to the Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements)
Regulations, 2015 as amended**

**The Board of Directors of
Advik Laboratories Limited**

We have reviewed the accompanying statement of unaudited Standalone financial results of M/s Advik Laboratories Limited for the quarter and nine months ended on 31st December, 2020. ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Attention is drawn to the following points:

- Due to default in payments of bank loans, the company's accounts have been classified as Non-Performing Assets (NPA) by the bank. Indian Overseas Bank has not charged interest on Cash credit & Term Loan Limits. During the period under review no provision has been made for such interest in the books of account of the company and to that extent bank's loan liability and total loss is understated by Rs. 872.62 lacs plus penal charges that the bank may charge. The amount disclosed in the Financial Statements is subject to confirmation, reconciliation and adjustments, if any.
- The company had recorded the cost of the investment at the face value of the equity shares issued and had not determined the fair value as required by Ind AS. The shares were not made available for physical verification. Hence, we are unable to comment upon the physical existence and express an opinion on the value of investment recorded.
- The stock of raw material and work in progress has been valued at cost price. In the current year there has been no production, it may have impact on profitability to the extent of its cost less realizable amount if any.

Place : New Delhi

Date : 12th February, 2021

For M/s. RMA & Associates LLP
Chartered Accountants
FRN: 000978N/N500062

New Delhi
(Amit Jain)
Partner
(Membership No. 503109)
UDIN: 21503109AAAAAW6962